Want to see CERS full AI Analyst Report?
CERS Stock Chart & Stats
$1.92
-$0.02(-1.22%)
At close: 4:00 PM EST
$1.92
-$0.02(-1.22%)
Day’s Range― - ―
52-Week Range$1.15 - $3.47
Previous CloseN/A
Volume302.69K
Average Volume (3M)2.55M
Market Cap
$627.15M
Enterprise Value$371.00
Total Cash (Recent Filing)$80.42M
Total Debt (Recent Filing)$97.36M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Jul 30, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding200,368,970
10 Day Avg. Volume2,146,772
30 Day Avg. Volume2,554,368
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)6.11
Price to Sales (P/S)1.90
P/FCF Ratio46.07
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.50Price Target Upside134.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$252.78M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueCerus’s business is anchored in single-use consumables tied to each treated unit, creating repeat purchase demand and predictable per-procedure revenue. Strong North American platelet kit growth and BCA adoption suggest durable customer retention and scalable recurring revenue as procedure volumes expand.
Sustained Top-line Acceleration & GuidanceConsistent high-teens CAGR and a raised 2026 revenue guide reflect durable commercial traction across products and regions. Visible demand and conservatively raised guidance improve planning, support operating leverage, and materially strengthen the company’s multi-quarter path toward sustained profitability.
Improved Leverage & Liquidity FlexibilityReduced indebtedness and amended credit facilities materially improve financial flexibility and lower refinancing risk. Greater access to a revolver and tranches provides working-capital capacity to support inventory builds, regulatory milestones, and commercialization without immediate dilutive financing.
Bears Say
Ongoing UnprofitabilityDespite narrowing losses and consecutive positive adjusted EBITDA quarters, GAAP profitability remains elusive. Persistent negative operating profit and EBITDA limit retained earnings, constrain reinvestment flexibility, and may require external financing to fund growth or milestones until sustained GAAP profits are achieved.
Gross Margin CompressionMaterial margin erosion driven by inflationary shipping, tariffs and FX reduces cash flow per unit and weakens the leverage benefit of revenue growth. Sustained lower gross margins constrain the company’s path to GAAP profitability and require either price recovery or structural cost reductions to restore margin sustainability.
Regulatory & Rollout Timing RiskKey catalysts—RBC CE Mark timing and broader IFC conversion—face regulatory review, audit and early commercial lumpiness. Delays or adverse review outcomes can materially postpone large revenue ramps, complicate multi-quarter planning, and increase the risk that anticipated scale benefits arrive later than expected.
Cerus News
CERS FAQ
What was Cerus Corporation’s price range in the past 12 months?
Cerus Corporation lowest stock price was $1.15 and its highest was $3.47 in the past 12 months.
What is Cerus Corporation’s market cap?
Cerus Corporation’s market cap is $627.15M.
When is Cerus Corporation’s upcoming earnings report date?
Cerus Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 9 days.
How were Cerus Corporation’s earnings last quarter?
Cerus Corporation released its earnings results on Apr 30, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.03.
Is Cerus Corporation overvalued?
According to Wall Street analysts Cerus Corporation’s price is currently Undervalued.
Does Cerus Corporation pay dividends?
Cerus Corporation does not currently pay dividends.
What is Cerus Corporation’s EPS estimate?
Cerus Corporation’s EPS estimate is -0.01.
How many shares outstanding does Cerus Corporation have?
Cerus Corporation has 200,368,970 shares outstanding.
What happened to Cerus Corporation’s price movement after its last earnings report?
Cerus Corporation reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went up 33.99%.
Which hedge fund is a major shareholder of Cerus Corporation?
Currently, no hedge funds are holding shares in CERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (134.38% Upside)
$4.50 (134.38% Upside)
Blogger Sentiment
Bullish
CERS Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $53.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
128.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.80%
Trailing 12-Months
Company Description
Cerus Corporation
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
CERS Stock 12 Month Forecast
Average Price Target
$4.50
▲(134.38% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―
Ownership Overview
5.76% Insiders
12.93% Mutual Funds
1.90% Other Institutional Investors
59.42% Public Companies and
Individual Investors